Cervical Cancer : Is Vaccination Necessary in India?

  • Farhath, Seema (Bharathiar University) ;
  • Vijaya, P.P. (Department of Biotechnology, Mohamed Sathak College of Arts and Science) ;
  • Mumtaj, P. (Department of Biotechnology, Mohamed Sathak College of Arts and Science)
  • Published : 2013.04.30


In India, cervical cancer is the most common woman-related cancer, followed by breast cancer. The rate of cervical cancer in India is fourth worldwide. Two vaccines, Gardasil and Cervarix, both targeting HPV-16 and 18 which account for 70% of invasive cervical carcinomas, are licensed in the United States and numerous countries worldwide. Both vaccine formulations have shown excellent efficacy with minimal toxicity in active female population but numerous questions arise in vaccinating like cost effectiveness, lack of proven efficacy against other HPV strains, social acceptance of HPV vaccination and other ethical issues. The main objective of this study is to emphasis the advantages and disadvantages of the vaccination in India.


  1. Ambika Satija Cervical Cancer In India (2010).
  2. Braaten KP, Laufer MR (2008). Human Papillomavirus (HPV), HPV-Related Disease, and the HPV Vaccine. Rev Obstet Gynecol, 1, 2-10.
  3. Cervical cancer-National Cancer Institute (2010). www.cancer. gov/cancertopics/factsheet/cancer-advances-in-focus/ cervical.
  4. Department Of Health And Human Services (2011). Centers for Disease Control and Prevention. and
  5. Cervarix. Fact sheet: HPV vaccine for protection against cervical cancer. (2010) http://www.
  6. FDA (US Food and Drug Administration) (2009). Information pertaining to labeling revision for Gardasil-Rockville: FDA.
  7. Ferenczy A, Franco E (2001). Cervical cancer screening beyond the year 2000. Lancet Oncol, 2, 27-32.
  8. Gauravi AM, Sharmila AP, Surendra SS (2011). An overview of prevention and early detection of cervical cancers. Indian J Med Paediatr Oncol, 32, 125-32.
  9. Herrero R (2009). Human papillomavirus (HPV) vaccines: limited cross-protection against additional HPV types. J Infect Dis, 199, 919-22.
  10. Kawana K, Yasugi T, Taketani Y (2009). Human papillomavirus vaccines: Current issues and future. Indian J Med Res, 130, 341-7.
  11. Munoz N, Castellsague X, de Gonzalez AB, Gissmann L (2006). HPV in the etiology of human cancer. Vaccine, 24, 1-10
  12. National Comprehensive Cancer Network (2011). NCCN Practice Guidelines in Oncology: Cervical Cancer Screening. v 1.
  13. Noller KL (2007). Intraepithelial neoplasia of the lower genital tract (cervix, vulva): Etiology, screening, diagnostic techniques, management. Comprehensive Gynecology. 5th ed. Philadelphia, Pa: Mosby Elsevier; chap 28.
  14. Sankaranarayanan R, Ferlay J (2006). Worldwide burden of gynecological cancer: the size of the problem. Best Pract Res Clin Obstet Gynaecol, 20, 207-25.
  15. Schiffman M, Wacholder S (2009). From India to the world-a better way to prevent cervical cancer. N Engl J Med, 360, 1453-5.
  16. Singh N (2005). HPV and Cervical cancer-prospects for prevention through vaccination. Indian J Med Paediatr Oncol, 26, 20-3.
  17. Smith RA, Cokkinides V, Brooks D, Saslow D, Brawley OW (2010). Cancer screening in the United States, a review of current American Cancer Society guidelines and issues in cancer screening. CA Cancer J Clin, 60, 99-119.
  18. Tovar JM, Bazaldua OV, Vargas L, Reile E (2008). Human papillomavirus, cervical cancer, and the vaccines. Postgrad Med, 120, 79-84.
  19. Winer RL, Hughes JP, Feng Q, et al (2006). Condom use and the risk of genital human papillomavirus infection in young women. N Engl J Med, 354, 2645-54.
  20. World Health Organization, authors. (2009) Weekly Epidemiological Record. Geneva; World Health Organization; Human papillomavirus vaccines.

Cited by

  1. Understanding and Responsiveness Level about Cervical Cancer and its Avoidance among Young Women of Pakistan vol.15, pp.12, 2014,
  2. A Novel Mutant of Human Papillomavirus Type 18 E6E7 Fusion Gene and its Transforming Activity vol.15, pp.17, 2014,
  3. Update knowledge on cervical cancer incidence and prevalence in Asia vol.16, pp.9, 2015,
  4. Knowledge and Attitudes Towards Human Papillomavirus (HPV) Among Academic and Community Physicians in Mangalore, India vol.32, pp.2, 2017,